The DUSP23 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HT29 human colorectal adenocarcinoma cell line, featuring loss-of-function disruption of the DUSP23 gene. This polyclonal population provides a heterogeneous mixture of edited cells, enabling robust and reproducible investigation of DUSP23 function in a cancer-relevant cellular context without clonal selection biases. The knockout model serves as a valuable tool for studying dual-specificity phosphatase biology and MAPK signaling regulation.
HT29 cells originate from a primary colorectal adenocarcinoma of a 44-year-old Caucasian female and display characteristic epithelial morphology with the ability to form polarized monolayers. They express intestinal epithelial markers such as cytokeratin 20 (CK20) and carcinoembryonic antigen (CEA), and are widely employed in colorectal cancer research, including studies of tumorigenesis, drug response, and mucin secretion. Their well-documented signaling networks and responsiveness to growth factors and cytokines make them an ideal host for interrogating MAPK pathway dynamics.
DUSP23 encodes a dual-specificity phosphatase that negatively regulates mitogen-activated protein kinase (MAPK) cascades by dephosphorylating phosphotyrosine and phosphoserine/threonine residues on ERK1/2, JNK1/2/3, and p38 MAPKs. Its activity is modulated by upstream stimuli such as EGF, TNF-??, oxidative stress, and various growth factors and cytokines. Through interaction with these MAPKs and scaffold proteins like KSR1, DUSP23 attenuates downstream phosphorylation of transcription factors including c-Jun, Elk-1, and ATF2, thereby controlling cell proliferation, differentiation, and stress responses. This places DUSP23 at a pivotal junction in the RAS-RAF-MEK-ERK, JNK, and p38 signaling axes.
In the HT29 colorectal adenocarcinoma model, disruption of DUSP23 function is predicted to dysregulate MAPK pathway output, potentially enhancing proliferative and survival signals. Given the critical role of MAPK signaling in colon cancer progression, this knockout model provides a relevant system to dissect DUSP23-mediated regulatory mechanisms that may contribute to tumor cell growth, apoptosis resistance, and chemoresistance. The polyclonal nature captures diverse editing events, offering a more physiologically representative landscape for studying gene function in heterogeneous cancer cell populations.
Researchers can employ these knockout cells in a broad range of functional assays, including western blotting and RT-qPCR for assessing DUSP23 expression and phospho-MAPK levels, phospho-kinase profiling to map signaling alterations, and RNA-seq for transcriptomic analyses. Cell-based phenotypic assays such as MTT and BrdU proliferation measurements, Annexin V and caspase-3/7 apoptosis assays, wound-healing and transwell migration studies, and colony formation assays facilitate comprehensive characterization of DUSP23 effects. Additionally, the knockout cells are suitable for drug sensitivity screening with MAPK pathway inhibitors, enabling exploration of therapeutic vulnerabilities. For further information, please contact Ascent Research.
